TITLE

All Stem Cell Transplantation for Chronic Myloproliferative Disorders and Myelodysplastic: The Question Is "When?"

AUTHOR(S)
Maziarz, Richard T.; Mesa, Ruben A.; Tefferi, Ayalew
PUB. DATE
August 2003
SOURCE
Mayo Clinic Proceedings;Aug2003, Vol. 78 Issue 8, p941
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Editorial. Discusses the appropriateness and timing of allogeneic hematopoietic stem cell transplantation (AHSCT) that may aid the clinician actively involved in the care of patients with chronic myeloproliferative disorders (CMPD) and myelodysplastic syndrome (MDS). CMPD and the three clinicopathologic entities that are classified as such; Experience of the Fred Hutchinson Cancer Research Center with AHSCT for myeloid metaplasia.
ACCESSION #
10880225

 

Related Articles

  • Henatopoietic Cell Transplantation for Adult Patients With Myelodysplastic Syndromes and Myeloproliferative Disorders. Benesch, Martin; Deeg, H. Joachim // Mayo Clinic Proceedings;Aug2003, Vol. 78 Issue 8, p981 

    Hematopoietic cell transplantation (HCT) is currently the only treatment with curative potential for myelodysplastic syndromes (MDS) and myeloproliferative disorders (MPD). Among patients with less advanced MDS, 3-year survival rates of 65% to 75% are achieved with HLAidentical related and...

  • Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia. Matsuda, K; Nakazawa, Y; Iwashita, C; Kurata, T; Hirabayashi, K; Saito, S; Tanaka, M; Yoshikawa, K; Yanagisawa, R; Sakashita, K; Sasaki, S; Honda, T; Koike, K // Leukemia (08876924);Jul2014, Vol. 28 Issue 7, p1545 

    The article discusses the study on myeloid progenitors with PTPN11 gene and nonRAS pathway gene mutations for treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia, a fatal mixed myeloproliferative and myelodysplastic disorder. The study involves seven cases of patients with...

  • Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantation. Brissot, Eolia; Cahu, Xavier; Guillaume, Thierry; Delaunay, Jacques; Ayari, Sameh; Peterlin, Pierre; Bourgeois, Amandine; Harousseau, Jean-Luc; Milpied, Noel; Bene, Marie-Christine; Moreau, Philippe; Mohty, Mohamad; Chevallier, Patrice // Annals of Hematology;Apr2015, Vol. 94 Issue 4, p663 

    In the myeloablative transplant setting, the early use of fluconazole prophylaxis provides a benefit in overall survival. Recent changes in transplantation practices, including the use of peripheral blood stem cells (PBSC) and/or reduced intensity conditioning (RIC) regimen may have favorably...

  • Sarcoma mieloide de intestino delgado en paciente aleucémico. Marco, José Ferrando; Morel, M.a Jesus Arilla; Navarro, José Tomás // Revista Española de Patología;apr-jun2009, Vol. 42 Issue 2, p147 

    A 19 year-old man with a clinical suspicion of Crohn's disease underwent surgery for intestinal occlusion in the distal jejunum. Macroscopically, a mass infiltrating the intestinal wall and adjacent mesenteric fat was seen. Histologically, the intestinal wall was infiltrated by poorly...

  • Cryptozoospermia with normal testicular function after allogeneic stem cell transplantation: A Case Report. L. Tauchmanovà; C. Alviggi; C. Foresta; I. Strina; A. Garolla; A. Colao; G. Lombardi; G. De Placido; B. Rotoli; C. Selleri // Human Reproduction;Feb2007, Vol. 22 Issue 2, p495 

    One of the most frequent consequences of allogeneic haemopoietic stem cell transplantation (allo-SCT) in both males and females is gonadal insufficiency. We report the case of a 27-year-old myelodysplastic male who developed azoospermia after allogeneic transplantation of haemopoietic stem cells...

  • Treatment of a severe extensive cutaneous chronic GVHD after allo-HSCT using glycerolyzed skin allografts and cultured epidermis from the same donor. Crocchiolo, R.; Nicolini, F.-E.; Sobh, M.; Ducastelle-Lepretre, S.; Labussiere, H.; Dubois, V.; Auxenfans, C.; Mojallal, A.; Damour, O.; Braye, F.; Michallet, M. // Bone Marrow Transplantation;Aug2011, Vol. 46 Issue 8, p1153 

    A letter to the editor is presented regarding the case of a 34-year-old woman with myelodysplastic syndrome-secondary acute myeloid leukemia (AML) and underwent a treatment of extensive cutaneous graft-versus-host-disease (GVHD) through allogeneic hematopoietic stem cell transplantation (HSCT).

  • Treatment of Myelodysplastic Syndromes. Kurtin, Sandra E.; Demakos, Erin P.; Hayden, Janet; Boglione, Claudia // Clinical Journal of Oncology Nursing;Jun2012 Supplement, Vol. 16, p23 

    Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid malignancies with variability in clinical presentation, disease trajectory, treatment goals, and expected outcomes. The treatment of patients with MDS, therefore, often differs from patient to patient. Tools are needed to aid...

  • A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Hasle, H; Niemeyer, C M; Chessells, J M; Baumann, I; Bennett, J M; Kerndrup, G; Head, D R // Leukemia (08876924);Feb2003, Vol. 17 Issue 2, p277 

    Myelodysplastic and myeloproliferative disorders are rare in childhood and there is no widely accepted system for their diagnosis and classification. We propose minimal diagnostic criteria and a simple classification scheme which, while based on accepted morphological features and conforming...

  • 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Field, T.; Perkins, J.; Huang, Y.; Kharfan-Dabaja, M. A.; Alsina, M.; Ayala, E.; Fernandez, H. F.; Janssen, W.; Lancet, J.; Perez, L.; Sullivan, D.; List, A.; Anasetti, C. // Bone Marrow Transplantation;Feb2010, Vol. 45 Issue 2, p255 

    Relapse remains a leading cause for treatment failure after hematopoietic cell transplantation (HCT) in patients with intermediate- or high-risk myelodysplastic syndrome (MDS). To discern the impact of 5-azacitine treatment pretransplant on the risk for relapse after HCT, we analyzed the post...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics